Craig-Hallum analyst Alexander Nowak lowered the firm’s price target on CareDx to $26 from $32 and keeps a Buy rating on the shares. The firm notes Q4 was largely in-line but important metrics fell short of expectations – testing services revenue and volume came in below its estimates and the full year 2023 guide at face-value was not particularly inspiring coming in below the Street.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CDNA:
- CareDx reports Q4 adjusted EPS (7c), consensus (9c)
- CareDx to present cellular transplant progress at Tandem Meetings
- Cathie Wood pours millions into these 2 stocks — this is what makes them attractive buys
- CareDx sees FY23 revenue $321.3M-$321.6M, consensus $347.69M
- CareDx reports preliminary Q4 revenue $81.9M-$82.2M, consensus $81.54M
